AP4 Rec'd PCT/PTTQ Substitute Fros P(1)(4)"Transmittal Form"

PCT

IL S. Retent and Trademark Office: ILS DRAN TAXABLE DE COMMERCE

100			mark Office; U.S. DEPARTMENT OF COMMERCE
Pile		Application Number	10/550,532
TRANSMITTAL		Filing Date	September 22, 2005
DEC 1 9 2005 (1) FORM		First Named Inventor	L.T. Duong et al.
		Art Unit	To be assigned
used for all correspondence after initial filing		Examiner Name	To be assigned
Total Number of Pages in This Submission	5	Attorney Docket Number	21259YP

C /				+	
R PAGE AND AND PROPERTY OF All correspondence after in	nitial filmal		Art Unit	To be assign	ned
transfer be used for all correspondence after in	miliai jiling)		Examiner Name	To be assign	ned
Total Number of Pages in This Submission		5	Attorney Docket Number	21259YP	
	ENCL	OSURES	(Check all that appl	(y)	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Licer Petit Prov	ion to Convisional Apper of Attorrage of Corrainal Disclauest for Ref	vert to a plication ney, Revocation espondence Address aimer	to Tech Appeal of App Appeal (Appea Proprie	Allowance Communication anology Center (TC) Communication to Board eals and Interferences Communication to TC Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please y below):
SICNATII	DE OF A	DDI ICAN	NT, ATTORNEY, OR	ACENT	
Name Nicole M. Beeler	KE OF A	HI LICA!	Registration No. (Attorn		45,194
Signature SICOCONDE	ele	r	1	Date	12/16/2005
I hereby certify that this correspondence is Postal Service with sufficient postage as P.O. Box 1450, Alexandria, Virginia 223	is being fa first class	acsimile tra mail in an	envelope addressed to:	or deposited	
Typed or printed name Barbara Muller		· · · · · · · · · · · · · · · · · · ·			
Signature 13 and	9M	. 00	Date	December 1	6. 2005

DEC 1 9 2005 - IN THE

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: La La Duard et al.

Serial No. 10/550,532

Filed: September 22, 2005

For: METHODS FOR TREATING ARTHRITIC CONDITIONS

Art Unit:	To be assigned		

Examiner: To be assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Babara Muller Date 12-16-05

INFORMATION DISCLOSURE STATEMENT

茂. 1.98(d), copies of references listed on the attached form that were submitted to or cited

by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120

		RELATED AP	PLICATION
	U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
th	is is inconvenient, additional copies will be submitted upon reques	st.	
6	5. In accordance with 37 C.F.R. 1.97, (check one)		
	the attached information is filed within three months of the filing da	ate of the captioned case.	
	the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the i	nailing of a first
	the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a	equest for continued
	the attached information is being filed more than three months afted. Office Action on the merits, but before the mailing date of a Final Action otherwise closes prosecution in the application. The enclosed authorized No. 13-2755 for the fee required under 37 C.F.R. 1.17(p)	Action, Notice of Allowance thorization is therefore give	e, or an action that
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application no Statement.		=
	each item of information contained in the information disclosure s from a foreign patent office in a counterpart application and this contained in §1.56(c) more than thirty days prior to the filing of the	ommunication was not rec	eived by any individu
	no item of information contained in this Information Disclosure Statering patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual desimonths prior to the filing of this Statement.	ne knowledge of the person	n signing the certifica
		Respectfully submitted,	
		Successive By. Nicole M. Beeler	eler
		•	olicant(s)
		Reg. No. 45,194 MERCK & CO., INC. Patent Dept., RY60-30 P.O. Box 2000	
		Rahway, N.J. 07065-090 (732)594-1077)7 -
		Date: December 16, 200	5 .

						Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
	Substitute for	form 1449A/PTO				COMPLETE IF KNOWN
	_INFOR	RMATIO	N DIS	CLOSURE	Application Number	10/550,532
	OIPE	eranderine en	37 A DI		Filing Date	September 22, 2005
	STATEMENT BY	YAP	PLICANI	First Named Inventor	Le T. Duong	
12	EC 1 9 2005	as many she			Group Art Unit	To be assigned
PATE	en con set	as many sne	ets as ne	ecessary)	Examiner Name	To be assigned
,	Sheet	1	of	2	Attorney Docket Number	21259YP
		•			-	

		÷	U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY
		6,008,207		Brenner, GS et al.	12/28/1999
					,

			FORE	IGN PATENT D	OCUMENTS			
		Foreign Patent Document				Date of Publication of		
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		

Examiner Signature		Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicate Patent and Trademyth Office. ILS DEPARTMENT OF COMMERCE.

e	bstitute for form 1449B/PTO				COMPLETE IF KNOWN	•
	NFORMATION 1	DIS	CLOSURE	CANT Filing Date September 22, 2005 First Named Inventor Le T. Duong Group Art Unit To be assigned	10/550,532	
C '	T A TERRATERIA DES	A D	DI ICANT	Filing Date	September 22, 2005	
3	TATEMENT BY	AP	PLICANI	First Named Inventor	Le T. Duong	
				Group Art Unit	To be assigned	
	(use as many sheets	as n	ecessary)	Examiner Name	To be assigned	
eet	2	of	2	Attorney Docket Number	21259YP	_

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
		Lehmann, HJ et al., Annals of the Rheumatic Diseases, p 530-533 (2002), "Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products"				
		Garnero, P et al., Bone, p 461-464 (2001), "The bisphosphonate zoledronate decreases Type II collagen breakdown in patients with Paget's disease of bone"				
		Muehleman, C et al., Osteoarthritis and Cartilage, p 226-233 (2002), "The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage"				
		Podworny, NV et al., The Journal of Rheumatology, p 1972-1982 (1999), "Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis"				
		Myers, SL et al., The Journal of Rheumatology, p 2645-2653 (1999), "Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis"				
		-				

Examiner Signature	Date Considered	